Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The goal of this trial is to determine the activity of erlotinib in a rationally selected
population of women with ER-negative, PR-negative, HER2/neu-negative, EGFR-positive breast
cancer. If erlotinib is shown to have activity, this could identify a form of targeted
therapy for this specific subset of breast cancer patients. In addition, it may identify a
subset of breast cancer patients with tumors that overexpress EGFR in whom other EGFR
targeted therapies could warrant further testing.